182 related articles for article (PubMed ID: 36882226)
1. Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab.
Routh ED; Woodcock MG; Beckabir W; Vensko SP; Serody JS; Vincent BG
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36882226
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Anders CK; Woodcock MG; Van Swearingen AED; Moore DT; Sambade MJ; Laurie S; Robeson A; Kolupaev O; Cuaboy LA; Garrett AL; McKinnon K; Cowens K; Bortone D; Calhoun BC; Wilkinson AD; Carey L; Jolly T; Muss H; Reeder-Hayes K; Kaltman R; Jankowitz R; Gudena V; Olajide O; Perou C; Dees EC; Vincent BG; Serody JS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121644
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
6. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Chun B; Pucilowska J; Chang S; Kim I; Nikitin B; Koguchi Y; Redmond WL; Bernard B; Rajamanickam V; Polaske N; Fields PA; Conrad V; Schmidt M; Urba WJ; Conlin AK; McArthur HL; Page DB
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086949
[TBL] [Abstract][Full Text] [Related]
7. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
8. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Kyte JA; Røssevold A; Falk RS; Naume B
J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
[TBL] [Abstract][Full Text] [Related]
9. The neoepitope landscape of breast cancer: implications for immunotherapy.
Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
[TBL] [Abstract][Full Text] [Related]
10. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies.
Kim KY; Yoon M; Cho Y; Lee KH; Park S; Lee SR; Choi SY; Lee D; Yang C; Cho EH; Jeon SD; Kim SH; Kim C; Kim MG
J Exp Clin Cancer Res; 2019 Aug; 38(1):363. PubMed ID: 31426843
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
12. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Barroso-Sousa R; Tolaney SM
Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
[TBL] [Abstract][Full Text] [Related]
14. Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
Otani Y; Mori K; Morikawa N; Mizutani M; Yasojima H; Masuyama M; Mano M; Masuda N
Immunotherapy; 2021 Feb; 13(3):189-194. PubMed ID: 33225795
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
17. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
18. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model.
Kang J; Lee HJ; Lee J; Hong J; Hong Kim Y; Disis ML; Gim JA; Park KH
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109084
[TBL] [Abstract][Full Text] [Related]
19. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]